Key Insights

Highlights

Success Rate

100% trial completion (above average)

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT02260505Phase 3Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

Showing all 1 trials

Research Network

Active Sponsors

  • Centre Leon Berard1

Top Investigators

Related Conditions

  • Kit Gene Mutation1
  • Gastrointestinal Stromal Tumors1
  • High Risk Of Recurrence1
  • Nonmetastatic1

Activity Timeline